Descripción de la empresa
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of chimeric antigen receptor cell therapy for light chain Amyloidosis and immune-mediated diseases within the United States and Australia. The company functions within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high R&D expenditures and regulatory scrutiny before products reach commercialization. Immix Biopharma, Inc. currently holds a market capitalization of $481.88M, while specific data for annual revenue and employee count is not available in the current reporting period. This market capitalization of $481.88M indicates that the market values the company's pipeline assets and potential future revenue streams at a level that reflects early-stage biotechnology valuations, despite the absence of substantial historical revenue figures.
Salud financiera
The company reports a Net Income (TTM) of $-29,438,612 and an EBITDA of $-29,710,668, while Revenue (TTM) is not available, revealing a cost structure where operating expenses significantly exceed any generated income. The Free Cash Flow stands at $-13,612,449, which signifies a substantial cash burn rate typical for clinical-stage biopharmaceutical companies investing heavily in trial phases rather than profit generation. Regarding margins, the Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, indicating that the company has not yet achieved profitability or that revenue figures are insufficient to calculate meaningful margins in the current reporting cycle. The balance sheet presents a contrast between cash resources of $100.41M and total debt of $1.07M, resulting in a Debt to Equity ratio of 1.14, suggesting a capital structure where equity obligations are substantial relative to cash on hand but leverage is not driven by traditional long-term debt. The Current Ratio is listed at 10.01, which indicates an exceptionally strong short-term liquidity position capable of covering current liabilities many times over, providing ample flexibility for operational needs. Furthermore, the Return on Equity is -55.0% and the Return on Assets is -29.3%, metrics that reveal management has not yet generated positive returns on the capital invested or the assets held, consistent with the pre-revenue stage of the business lifecycle.
Evaluación de valoración
Valuation multiples for Immix Biopharma, Inc. present a mixed picture, with a Forward P/E of -12.49 and a Trailing P/E (TTM) listed as N/A due to negative earnings, implying that traditional earnings-based valuation models are not applicable until the company transitions to profitability. The Price to Book ratio is 5.13, indicating that the market values the company's equity at more than five times its book value, a premium often seen in biotech firms where intangible assets like patents and clinical data are not fully captured on the balance sheet. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of -12.86, suggesting that investors are pricing the stock based on pipeline potential rather than current cash flows or sales performance. The stock has traded between a 52-Week High of $11.61 and a 52-Week Low of $1.34, placing the current price within a range that reflects significant volatility typical of speculative growth stocks. The Beta value is 0.21, indicating that the stock's price volatility is substantially lower than the broader market, suggesting that the asset class or specific stock characteristics dampen price swings relative to the overall index.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning that historical growth rates cannot be calculated to determine if earnings are growing faster or slower than revenue. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that all available earnings and cash flow are retained and reinvested into research, development, and clinical trials rather than distributed to shareholders. The absence of a dividend yield aligns with the company's lifecycle stage, where capital preservation and funding of the chimeric antigen receptor cell therapy pipeline take precedence over income distribution to investors. Consequently, the overall growth and income profile is defined by zero current income generation and a complete reliance on retained capital to fund future product development and market entry strategies.